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Abstract 
 
Objectives Macrophages are central to the inflammatory processes driving 
rheumatoid arthritis (RA) synovitis. The molecular pathways that are induced in 
synovial macrophages and thereby promote RA disease pathology remain poorly 
understood. 
Methods We used microarray to characterise the transcriptome of synovial fluid 
(SF) macrophages compared to matched peripheral blood monocytes from RA 
patients (n=8).  
Results Using in silico pathway mapping, we found that pathways downstream of 
the cholesterol activated Liver X Receptors (LXRs), and those associated with 
toll-like receptor (TLR) signalling, were up-regulated in SF macrophages. 
Macrophage differentiation and TNFα promoted the expression of LXRα. 
Furthermore, in functional studies we demonstrated that activation of LXRs 
significantly augmented TLR driven cytokine and chemokine secretion.  
Conclusion The LXR pathway is the most up-regulated pathway in RA synovial 
macrophages and activation of LXRs by ligands present within SF augments TLR 
driven cytokine secretion. Since the natural agonists of LXRs arise from 
cholesterol metabolism, this provides a novel mechanism that can promote RA 
synovitis. 
 
Abstract word count: 160 
 
  
Introduction 
Rheumatoid arthritis (RA) is a debilitating autoimmune inflammatory 
condition of unknown etiology. RA affects approximately 1% of the population 
and is associated with increased morbidity, reduced life expectancy, a 
heightened degree of social burden and economic cost. The primary site of 
inflammation is the synovium, characterised by hyperplasia and vascularisation, 
inflammatory cell infiltration, hypoxia and destruction of adjacent cartilage and 
bone. This ultimately leads to irreversible destruction of the joint and impaired 
mobility. Although the use of biologic therapeutics has considerably improved 
clinical outcomes and prognosis, they remain effective in only a proportion of 
patients and rates of long-term remission achieved remain low. There is therefore 
an ever-greater need to understand the cellular and molecular processes by 
which pathology is mediated to develop future therapeutics. 
Macrophages constitute the major leukocyte population within the synovial 
inflammatory infiltrate (≥40%).[1] Synovial macrophage numbers directly 
correlate with measures of disease activity and severity including; CRP, ESR, 
swollen joint count, synovial lining layer vascularity and thickness, the presence 
of citrillinated peptides and radiologic score.[2, 3] Furthermore, the number of 
synovial lining layer CD68+ macrophages provide a useful biomarker of response 
upon successful clinical intervention in the context of clinical trials.[4-7] As 
macrophages are a major source of IL-6 and TNFα, the recent success of anti-
cytokine therapeutics supports the notion that macrophage targeted therapies 
may be beneficial for the treatment of RA (reviewed in,[8]) and highlight a central 
role for macrophages in the progression of human disease pathology. 
There are multiple mechanisms by which synovial macrophages may 
contribute towards the inflammatory burden and joint destruction in RA.[9] Pro-
inflammatory cytokines and immune complexes present in plasma induce early 
activation of CD14+ monocytes, up-regulation of integrins and chemokine 
receptors (e.g. CCR1 and CCR2) and trans-endothelial migration of monocytes 
into the synovium. Monocytes accumulate in the synovium where high 
concentrations of M-CSF and GM-CSF enhance monocyte to macrophage 
differentiation and maturation.  
The advent of transcriptional array techniques allows definitive 
characterisation of the pathways that are active within a given cell population. We 
therefore adopted a microarray-based approach to elucidate the molecular 
pathways that are activated in RA Synovial Fluid (SF) macrophages to identify 
novel pathways that could drive disease pathology. Using this approach we now 
report the unexpected prominence of the cholesterol activated Liver X Receptor 
(LXR) pathway that integrates with TLR pathways to enhance synovial cytokine 
secretion. 
Methods 
Reagents 
GW3965 (Merck UK) was dissolved in DMSO. 
Tissues and patient samples 
Blood, SF and synovial membrane samples were obtained from patients with RA 
after obtaining their written informed consent. Patient numbers and 
characteristics are shown in Supplementary Table 1. This study complied with 
the World Medical Association Declaration of Helsinki and was approved by the 
Glasgow East Ethics Committee. All samples were processed immediately upon 
arrival by centrifugation on a histopaque density gradient to separate out the 
peripheral blood mononuclear cells followed by MACS CD14 positive 
selection.[10] The samples were lysed in Trizol and stored at -70oC prior to RNA 
extraction. Cell purities were typically >95% (data not shown). 
 
RNA purification and analysis 
Single cell suspensions were lysed in buffer RLT or Trizol and the RNA extracted 
following the RNeasy micro kit (Qiagen). Gene expression was analysed using 
SYBR green QRT-PCR master mix on an ABI7900HT and SDS 2.3 software 
(Applied Biosystems). Gene expression was normalised to TATA binding protein 
(TBP) or GAPDH. Primer Sequences are shown in Supplementary Table 2.  
Microarray analysis 
The integrity of RNA was ensured by analysis of ribosomal 18S and 28S RNA 
intensity using an Agilent 2100 Bioanalyser (Agilent Technologies). Following 
genomic DNA digestion cDNA was synthesised, fragmented and biotin labelled 
(FL-Ovation™ cDNA Biotin Module V2 kit  -Nugen Technologies). An Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 Array was performed using a 
GeneChip® Scanner 3000. Background correction and normalisation for each 
probe set on the GeneChips was determined by the RMA algorithm using R and 
Bioconductor and quality assured using arrayQualityMetrics.[11] Further analysis 
and differential gene expression studies were carried out using oneChannelGUI. 
A pfp (predictor of false positive) value of 0.05 was chosen to determine 
differentially expressed genes. Pathway analysis was performed using Ingenuity 
Pathway Analysis (IPA - Ingenuity Systems). The microarray data produced in 
this study is MIAME compliant 
(http://www.mged.org/Workgroups/MIAME/miame.html) and will be submitted to 
the ArrayExpress database (www.ebi.ac.uk/arrayexpress) once the manuscript is 
accepted for publication. 
Cell culture 
Cells were cultured at a density of 1.0 x105/ well in a 96 well plate (Corning) and 
matured to a macrophage phenotype as previously described.[10, 12] Cells were 
pre-incubated with GW3965 or vehicle at the indicated concentration for 48 hours 
prior to addition of TLR ligands; 100 ng/ml ultra pure lipoplysacchardide (LPS - 
Calbiochem), 10 µg/ml Lipoteichoic acid (LTA), 10 µg/ml Pam3CSK4 or 1 µg/ml 
CL097 (Autogen) for 24 hours.  
Cytokine analysis 
The concentration of cytokines in cell culture supernatants was analysed by 
ELISA or luminex as previously described.[10]  
Immunofluorescence 
5 µM sections were deparaffinised, rehydrated and epitope retrieval was 
performed using citrate buffer followed by incubation with 20% horse serum. 
Primary antibodies were incubated overnight at 4oC in 5% serum/ TBST at final 
concentration of 2.5 µg/ml LXRα (Abcam – clone PPZ0412), 2.6 µg/ml LXRβ 
(Santa Cruz – polyclonal), 2.5 µg/ml CD68 (Dako – clone PG-M1) or isotype 
controls (Dako). Biotinylated secondary antibodies were incubated for 30 min in 
5% serum/TBST followed by incubation with Avidin-D fluorochrome conjugates 
(Vectorlabs; LXRα/β - Fluorescein or CD68 - Texas Red) for 45 min in PBS. 
Slides were mounted in vectashield containing DAPI (Vectorlabs) and visualised 
under a fluorescent microscope (Axiovert S100 and Openlab software).  
Statistical analysis 
Results are displayed as mean ± standard deviation. Statistical analysis was by 
paired Students t test, Wilcoxon paired t test or Two-Way Anova using the Graph 
Pad Prism 4 software.  The significance of association between the differentially 
expressed genes and canonical pathways within IPA was determined using 
Fisher’s exact test and corrected using Benjamini-Hochberg correction for 
multiple testing. 
Results 
 
Analysis of the synovial fluid derived macrophage transcriptome 
To determine the gene expression profile that defines an RA SF 
macrophage, microarray analysis was performed on sorted SF macrophages and 
the transcriptome compared to that of matched peripheral blood monocytes 
obtained from eight subjects with RA. Only genes that were significantly 
differentially expressed with p ≤ 0.05 between the blood and synovium in all eight 
donors were considered for further analysis. From a total of 54,675 detectable 
transcripts 8,303 were significantly differentially expressed between the blood 
and the synovium (Figure 1A & B). We examined the transcriptional relationships 
between SF macrophages and peripheral blood monocytes by principal 
component analysis. Importantly, the transcriptional profile for each of the sample 
populations clustered together but separately from each other indicating 
conservation of patterns of gene expression in each group but that SF 
macrophages have a transcriptionally distinct profile of gene expression from that 
of the peripheral blood monocytes (Figure 1C). It is likely therefore that the RA 
synovial micro-environment induces specific transcriptional changes upon entry 
of monocytes into the synovium that may drive disease pathology. 
 
The LXR pathway is highly up-regulated in RA synovial fluid macrophages 
We next examined the canonical biological pathways most associated with 
this transcriptional profile using IPA. The pathway most significantly induced in 
SF macrophages was the LXR/RXR nuclear receptor activated pathway 
(Supplementary Table 3 and Figure 2A). By microarray LXRα expression was up-
regulated by approximately 2.1 fold whilst the expression of LXRβ was not 
changed (Figure 2B and Supplementary Table 4). LXRs are nuclear receptor 
transcription factors that upon activation by oxidised cholesterol derivatives drive 
the expression of a large variety of transcriptional target genes. IPA analysis also 
revealed increased expression of known downstream target genes particularly, 
ATP Binding Cassette (ABC) A1 and ABCG1, Apolipoprotein (Apo) C1, Apo C2, 
Lipoprotein Lipase (LPL) and Phospholipid Transfer Protein (PLTP) (Figure 2A 
and Supplementary Table 4).  
  
Confirmation of LXR activation and induction of downstream gene expression 
To confirm the microarray results we used QRT-PCR to analyse changes 
in the level of gene expression. Consistent with the microarray results the 
expression of LXRα was significantly higher in SF macrophages compared to 
matched peripheral blood monocytes in all donors (Figure 3). In contrast, the 
expression of LXRβ was significantly downregulated. Furthermore, we confirmed 
that the expression of ABCA1, ABCG1 LPL, PLTP, ApoE, ApoC1 and ApoC2 
were significantly increased (Figure 3) which suggests that the level of LXR 
activation is increased in monocytes upon entry into the RA synovial micro-
environment.  
 
LXR protein is present in synovial macrophages  
We next sought to demonstrate the presence of LXRα and LXRβ protein 
particularly within synovial macrophages. Sections derived from RA synovial 
membrane biopsies were stained with antibodies against either LXRα or LXRβ in 
combination with CD68. We detected LXRα (40%) and LXRβ (36%) positive 
macrophages in RA synovial membranes (Figure 4A-C). 
 
Macrophage differentiation up-regulates LXRα expression 
Migration into the synovium induces the differentiation of monocytes into 
macrophages.[13, 14] We therefore examined the level of LXRα expression 
during the differentiation of healthy peripheral blood monocytes to a macrophage 
phenotype. In all four donors tested, LXRα was significantly increased between 
10 and 150 fold over 6 days (Figure 5A). In contrast, LXRβ was significantly 
down-regulated by approximately two fold (Figure 5B) whereas the basal level of 
ABCA1 expression, as a reporter of LXR activation, was not significantly different 
between monocytes and macrophages, but could be increased by addition of the 
LXR agonist GW3965 (Figure 5C). Together these results suggest that whereas 
macrophage differentiation can alter the relative level of LXRα and LXRβ 
expression it is not sufficient alone to induce activation of the LXR pathway. 
Studies have previously shown that administration of GW3965 to LPS-
activated monocytes or macrophages potentiates the secretion of pro-
inflammatory cytokines.[10, 15] To determine if the difference in the level of LXR 
expression between monocytes and macrophages impacts the level of 
subsequent cytokine secretion we treated syngeneic monocytes and 
macrophages for 48 hours with GW3965 followed by stimulation with 100 ng/ml 
LPS. After 24 hours the concentration of TNFα in cell culture supernatants was 
measured by ELISA. In agreement with previous observations LXR agonism 
significantly increased the secretion of TNFα from LPS stimulated monocytes 
(Figure 5D and,[10]). In comparison to monocytes at the same concentration of 
GW3965, macrophages secreted significantly higher levels of TNFα in response 
to stimulation with LPS suggesting that the higher level of LXR expression in 
macrophages enhances inflammatory cytokine secretion.  
 
TNFα augments the expression of LXRα in human macrophages 
Differentiation of monocytes to macrophages enhances the level of LXR 
expression. However, TNFα is central to the pathology of RA and has previously 
been shown to increase the expression of LXRα in rabbit adipocytes.[16] To test 
whether TNFα effects LXR expression in human macrophage we treated M-CSF 
matured macrophages with 25 ng/ml TNFα for 4 hours. Addition of TNFα 
modestly, but significantly, increased LXRα expression two-fold whereas the 
expression of LXRβ and ABCA1 was unchanged (Figure 5 E-G). Treatment of 
macrophages with up to 100 ng/ml IL-6 did not change the expression of LXRα, 
LXRβ or ABCA1 (data not shown).  
 
LXR activation potentiates TLR driven cytokine secretion in human macrophages 
Our microarray analysis also showed that the expression of genes known 
to be involved in the inhibition of Retinoid X Receptor (RXR) function were highly 
significantly up-regulated in SF macrophages (Supplementary Table 3). This 
pathway consisted mainly of genes that are downstream of Toll-like receptors 
(TLRs) and that are transcriptionally up-regulated upon TLR ligation. 
Furthermore, TLRs have been widely implicated as potential drivers of RA 
disease pathology. In particular TLR2, TLR4, TLR7 and TLR8 have all been 
shown to be expressed at higher levels in RA synovial macrophages and 
potential exogenous and endogenous TLR ligands have been identified in RA 
SF.[17-21] This was of particular interest as LXR agonism has previously been 
shown to potentiate macrophage cytokine secretion induced by TLR4 ligation 
with LPS (Figure 5D and,[10, 15]). However, the effect of LXR agonism upon 
cytokine secretion induced by ligation of TLR2, TLR7 and TLR8 is unknown. 
Human M-CSF matured macrophages were cultured in the presence of GW3965 
for 48 hours prior to stimulation with TLR ligands; LPS (TLR4) and CLO97 
(TLR7/8). TLR2 (TLR1/2 or TLR2/6) can be stimulated with either PAM3CSK4 or 
LTA; however, these ligands exert differential effects in macrophages and 
therefore both of these TLR2 ligands were used in parallel.[22] In accordance 
with our previous findings, LXR agonism by addition of GW3965 significantly 
increased the secretion of TNFα from LPS stimulated human macrophages in a 
dose dependent manner (Figure 6A). Furthermore, LXR agonism augmented the 
secretion of TNFα from macrophages stimulated with ligands for TLR2 (Figure 
6B and C) or TLR7/8 (Figure 6D). Luminex analysis of cell culture supernatants 
showed that this was not specific to TNFα as the secretion of other pro-
inflammatory cytokines, IL-1β, IL-6, IL-12 and G-CSF, and inflammatory 
chemokines, MIP-1α (CCL3) and MIP-1β (CCL4), that are typically secreted upon 
TLR ligation were also increased from macrophages stimulated with LPS (Figure 
6E), LTA (Figure 6F) PAM3CSK4 (Figure 6G) and CL097 (Figure 6H). There was 
a significant increase in IL-1RA but no significant difference in the concentration 
of IL-10 (Figure 6F, G and H and data not shown).  
Discussion 
By adopting a hypothesis free approach we have utilised microarray 
technology to elucidate the molecular pathways that are induced within RA SF 
macrophages. Importantly, we have shown that the transcriptome of SF 
macrophages differs considerably compared to peripheral blood monocytes. 
Furthermore, we have shown that the LXR pathway is highly induced and is a 
novel potential driver of RA disease pathology that is in part mediated by 
augmentation of TLR induced cytokine secretion. 
 Our studies show that the expression of LXRα is increased during 
macrophage differentiation in vitro, whilst the expression of LXRβ is down-
regulated. This can be further augmented by the pro-inflammatory cytokine TNFα 
which is a hallmark of the inflamed synovium. LXRs are activated by a variety of 
oxidised cholesterol derivatives.[23] It is therefore interesting to find that a lipid-
activated pathway is the most up-regulated pathway in SF macrophages as RA is 
associated with dyslipidemia i.e. high serum cholesterol and triglycerides and an 
atherosclerotic like phenotype.[24-26] Furthermore, several studies have 
demonstrated that the concentration of cholesterol and the cholesterol transport 
lipoproteins are elevated in SF.[27] Further studies are therefore required to 
characterise the synovial lipidome in detail. However, we speculate that the 
elevated levels of cholesterol in the synovium may lead to the subsequent 
induction of the LXR pathway, which may drive synovial inflammation. In 
agreement with this we have previously shown that dual activation of LXRα and 
LXRβ greatly enhances the onset and severity of disease in a murine model of 
collagen-induced arthritis.[10, 28] Taken together these studies demonstrate a 
potential pro-inflammatory effect of LXR activation and for the first time show that 
LXR activated pathways contribute a major role in human pathology by driving 
inflammatory cytokine secretion, which may potentiate the progression of 
synovitis. 
The mechanism(s) by which LXR activation drives RA disease pathology 
are unknown. However, the microarray analysis revealed that the pathways 
induced by TLR ligation were highly increased in the SF macrophages consistent 
with similar observations in the literature.[18, 29] The TLRs expressed on 
macrophages bind a variety of viral and bacterial derived products, e.g. bacterial 
lipoproteins (TLR1/2/6), lipopolysaccharide (TLR4) and single stranded RNA 
(TLR7/8). Whilst bacterial cell wall fragments, peptidoglycan and double stranded 
DNA have been identified within the synovium it is now well recognised that TLRs 
can be activated by endogenous self proteins such as heat-shock proteins and 
double stranded RNA released from necrotic synoviocytes.[18, 30] LXR 
activation is known to potentiate cytokine secretion from LPS activated human 
macrophages; this is in part achieved through increased expression of TLR4.[10, 
15] Here we have extended these studies and shown that activation of the LXR 
pathway also leads to a dramatic increase in cytokine secretion driven by TLR 1/ 
2, TLR2/6 and TLR 7/8. These results are of particular interest as the expression 
of TLR2 is up-reulgated upon differentiation of monocytes to macrophages, which 
can lead to the enhancement of Th17 cells.[31, 32] Furthermore, such studies 
suggest that TLR induced cytokine secretion in RA SF macrophages is mediated 
mainly through TLR2. However, although we have confirmed that LXR activation 
increases the expression of TLR4, the expression of TLR1, TLR2, TLR6, TLR7 
and TLR8 were not changed (data not shown). Therefore, the mechanism by 
which LXR activation promotes cytokine secretion induced by ligation of TLR1/2, 
TLR2/6 and TLR7/8 is unknown.  
 Overall, our results support the hypothesis that the dyslipidemia 
associated with arthritis may enhance the inflammatory aspect of disease and 
that this may be in part mediated through activation of the LXRs. Furthermore, 
our data help support clinical findings that reducing the atherosclerotic burden in 
RA may ameliorate the inflammatory aspect of disease and improve long-term 
prognosis in RA. 
 
 
Acknowledgments and funding 
Funding was provided by MASTER SWITCH European community grant, 
Medical Research Council (UK), the Nuffield Foundation Oliver Bird Rheumatism 
programme, Arthritis Research UK and the Iraqi Ministry of Higher Education and 
Scientific Research. 
 
Competing interests 
Sabina Patel was employed by GlaxoSmithKline. 
 
Author contributions 
 
Darren L Asquith, Lucy E Ballantine, Jagtar Singh Nijjar, Manhal Khuder 
Makdasy, Sabina Patel, Pamela B Wright, James H Reilly, Shauna Kerr, Mariola 
Kurowska-Stolarska and J Alastair Gracie, all contributed towards the provision 
of samples, analysis and interpretation of data, study design(s), the critical 
revision of the article and contributed towards the intellectual content. 
 
Darren L Asquith, Lucy E Ballantine, Jagtar Singh Nijjar and Iain B McInnes also 
drafted the manuscript. 
 
All authors approved the final version of the manuscript. 
 
References  
1. Sack U, Stiehl P, Geiler G. Distribution of macrophages in rheumatoid 
synovial membrane and its association with basic activity. Rheumatol Int 
1994;13:181-186. 
2. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial 
membrane with macrophage subsets and polymorphonuclear cells reflects global 
disease activity in spondyloarthropathy. Arthritis Res Ther 2005;7:R359-369. 
3. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage 
populations and articular damage in rheumatoid arthritis. Arthritis Rheum 
1996;39:115-124. 
4. Bresnihan B, Pontifex E, Thurlings RM, et al. Synovial tissue sublining 
CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis 
clinical trials: consistency across centers. J Rheumatol 2009;36:1800-1802. 
5. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue 
macrophages: a sensitive biomarker for response to treatment in patients with 
rheumatoid arthritis. Ann Rheum Dis 2005;64:834-838. 
6. Jahangier ZN, Jacobs JW, Kraan MC, et al. Pretreatment macrophage 
infiltration of the synovium predicts the clinical effect of both radiation 
synovectomy and intra-articular glucocorticoids. Ann Rheum Dis 2006;65:1286-
1292. 
7. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone 
on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. 
Arthritis Rheum 2004;50:3783-3791. 
8. Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted 
anti-TNF therapy? Ann Rheum Dis 2010;69 Suppl 1:i97-99. 
9. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in 
rheumatoid arthritis. Macrophages. Arthritis Res Ther 2007;9:224. 
10. Asquith DL, Miller AM, Hueber AJ, et al. Liver X receptor agonism 
promotes articular inflammation in murine collagen-induced arthritis. Arthritis 
Rheum 2009;60:2655-2665. 
11. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics--a 
bioconductor package for quality assessment of microarray data. Bioinformatics 
2009;25:415-416. 
12. Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene 
expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 
2006;54:2711-2721. 
13. Ridley MG, Kingsley G, Pitzalis C, et al. Monocyte activation in rheumatoid 
arthritis: evidence for in situ activation and differentiation in joints. Br J Rheumatol 
1990;29:84-88. 
14. Koch AE, Burrows JC, Skoutelis A, et al. Monoclonal antibodies detect 
monocyte/macrophage activation and differentiation antigens and identify 
functionally distinct subpopulations of human rheumatoid synovial tissue 
macrophages. Am J Pathol 1991;138:165-173. 
15. Fontaine C, Rigamonti E, Nohara A, et al. Liver X receptor activation 
potentiates the lipopolysaccharide response in human macrophages. Circ Res 
2007;101:40-49. 
16. Zhao SP, Dong SZ. Effect of tumor necrosis factor alpha on cholesterol 
efflux in adipocytes. Clin Chim Acta 2008;389:67-71. 
17. Enevold C, Radstake TR, Coenen MJ, et al. Multiplex screening of 22 
single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in 
rheumatoid arthritis. J Rheumatol 2010;37:905-910. 
18. Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like receptors 
3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like 
receptor expression in early and longstanding arthritis. Arthritis Rheum 
2008;58:3684-3692. 
19. Huang Q, Ma Y, Adebayo A, et al. Increased macrophage activation 
mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 
2007;56:2192-2201. 
20. Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like 
receptors 2 and 4 in rheumatoid synovial tissue and regulation by 
proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-
gamma. Arthritis Rheum 2004;50:3856-3865. 
21. Sacre SM, Lo A, Gregory B, et al. Inhibitors of TLR8 reduce TNF 
production from human rheumatoid synovial membrane cultures. J Immunol 
2008;181:8002-8009. 
22. Long EM, Millen B, Kubes P, et al. Lipoteichoic acid induces unique 
inflammatory responses when compared to other toll-like receptor 2 ligands. 
PLoS One 2009;4:e5601. 
23. Janowski BA, Willy PJ, Devi TR, et al. An oxysterol signalling pathway 
mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-731. 
24. van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and 
inflammation: serial measurements of the lipid profile of blood donors who later 
developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-188. 
25. van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in 
rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin 
Arthritis Rheum 2011;40:389-397. 
26. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: 
potential mechanisms and solutions. Curr Opin Rheumatol 2005;17:286-292. 
27. Ananth L, Prete PE, Kashyap ML. Apolipoproteins A-I and B and 
cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism 
1993;42:803-806. 
28. Asquith DL, Miller AM, Reilly J, et al. Simultaneous activation of the liver X 
receptors (LXRalpha and LXRbeta) drives murine collagen-induced arthritis 
disease pathology. Ann Rheum Dis 2011;70:2225-2228. 
29. Tamaki Y, Takakubo Y, Hirayama T, et al. Expression of Toll-like 
receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 
2011;38:810-820. 
30. van der Heijden IM, Wilbrink B, Tchetverikov I, et al. Presence of bacterial 
DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis 
and other arthritides. Arthritis Rheum 2000;43:593-598. 
31. He Z, Shotorbani SS, Jiao Z, et al. HMGB1 promotes the differentiation of 
Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with 
rheumatoid arthritis. Scand J Immunol 2012;76:483-490. 
32. Iwahashi M, Yamamura M, Aita T, et al. Expression of Toll-like receptor 2 
on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid 
arthritis. Arthritis Rheum 2004;50:1457-1467. 
 
 Rheumatoid arthritis patient characteristics 
Number of patients 
Mean age (years) 
Female : Male 
Mean disease duration (years) 
Mean ESR (mm/hr) 
Mean CRP (mg/L)  
RF positive (%) 
Disease modifying anti-rheumatic drug use (%) 
Anti TNFα therapy (%) 
8 
68 
5 : 3 
12.2 
86 
107 
87.5 
62.5 
1* 
 
Supplementary Table 1. Clinical characteristics of the rheumatoid arthritis 
patients that contributed samples towards the microarray analysis; * Anti-TNF 
therapy ceased due to patient becoming resistant to therapy. 
  Primer Sequence (5’ – 3’) 
TBP FWD: AGACCTTCCTGTTTACCCTTGCCA 
REV: TAGCTGTGGGTGACTGCTTGGATT 
ABCA1 FWD: ACACCTGCAGTTCATCAGTGGAGT 
REV: ATAATGACCAGTGTGGCAGGGACA 
LXRα FWD: CAGGGCTGCAAGTGGAATTCATCA  
REV: GAGCAAGGCAAACTCGGCATCATT 
LXRβ FWD: ACTTCACCTACAGCAAGGACGACT  
REV: AAGATGTTGATGGCGATGAGCAGG 
ApoC1 FWD: AGGACAGGACCTCCCAACCAA 
REV: GGCTGGGCCTTCCAAGACGAT 
ApoC2 FWD: GGATTTGAGGTCCAGGGGACC 
REV: TGGGCGGCTGTCTTTGCTGAC 
ApoE FWD: GAACTGAGGGCGCTGATGGAC 
REV: CTCCGCCACCGGGGTCAGTT 
LPL FWD: TCATCAGTCGGTCCGCGCCT 
REV: AATCTCTTCTTTGGTCGGCGG 
PLTP FWD: GGATCCCGCTGGACGGATGAA 
REV: GCTGGTTGAGGAGGAAGCGCA 
Supplementary Table 2. The sequence of the forward (FWD) and reverse (REV) 
primers used for analysis of human gene expression by SYBR green QRT-PCR. 
 Canonical pathways up-regulated in RA synovial macrophages p value 
LXR/RXR activation 
Hepatic fibrosis/ hepatic stellate cell activation 
Role of macrophages, fibroblasts and endothelial cells in RA 
LPS/IL-1 mediated inhibition of RXR function 
Coagulation system 
3.96 x 10-7 
2.27 x 10-5 
7.2 x 10-5 
1.07 x 10-4 
1.98 x 10-4 
 
Supplementary Table 3. The top five significantly up-regulated canonical 
pathways in synovial fluid macrophages compared to syngeneic peripheral blood 
monocytes of patients with RA as assessed by use of Ingenuity Pathway 
Analysis. Fisher’s exact test. 
 Gene Gene 
expression 
Log2  
fold 
change 
pfp 
value 
Reported functions 
LXRα/β 
 
 
ABCA1/G1 
 
 
ApoC1 
 
 
 
ApoC2 
 
 
ApoE 
 
 
 
LPL 
 
2.12/1 
 
 
2.41 
 
 
6.38 
 
 
 
4.58 
 
 
3.24 
 
 
 
6.09 
 
0 
 
 
0 
 
 
0 
 
 
 
0 
 
 
0 
 
 
 
0 
 
Transcription factors that are activated by 
ligation of oxidised cholesterol derivatives. 
 
Lipid transporters that promote reverse 
cholesterol transport in macrophages. 
 
Components of VLDL and HDL lipid particles, 
inhibits LPL and promotes LPS induced TNFα 
secretion from macrophages.  
 
Part of VLDL particles and activates LPL to 
induced triglyceride hydrolysis. 
 
Transports cholesterol as part of LDL and VLDL 
particles from the periphery for degradation in 
the liver and excretion in bile. 
 
A triglyceride hydrolase and acts as a receptor 
for HDL uptake.  
 PLTP 
 
5.14 
 
0 
 
Transfer of phospholipids from VLDL particles 
to HDL during reverse cholesterol transport. 
Supplementary Table 4. Log 2 fold change in the expression of genes that form 
the LXR/RXR pathway as identified by microarray analysis by comparison of the 
transcriptome of synovial fluid macrophages to peripheral blood monocytes. Liver 
X receptor (LXR), ATP binding cassette A1/ G1 (ABCA1/G1), Apolipoprotein 
(Apo), lipoprotein lipase (LPL) and phospholipid transfer protein (PLTP). n = 8 RA 
patients. Rank Product statistic.  
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Figure 1. Microarray gene expression profiles of peripheral blood monocytes and synovial 
fluid resident macrophages. Microarray analysis was performed on RNA extracted from 
peripheral blood (PB) monocytes and synovial fluid (SF) resident macrophages of patients 
with rheumatoid arthritis (RA). (A) Graphical representation of the number and magni-
tude of transciptional changes between peripheral blood and synovial fluid macrophages. 
(B) Microarray analysis identified 8303 genes that were differentially expressed between 
the blood and synovial  monocytes. (C) Principal Component Analysis revealed that syno-
vial fluid monocytes (blue) have a  uniquely distinct pattern of gene expression compared 
to syngenic peripheral blood monocytes (red). n = 8 independent donors.
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Figure 2. The Liver X Receptors pathway is the most significantly upregulated 
pathway in RA synovial macrophages. (A) A Schematic of the molecular 
pathways leading to the activation of the Liver X Receptors (LXRs) and the 
downstream LXR target genes. Cholesterol taken up into the cell by 
scavenger receptors (CD36) and the Low density lipopoprotein receptor 
(LDLR) is oxidised to form oxysterol ligands which can activate the LXRs. LXR 
activation induces the expression of down stream transcriptional target 
genes (ABCA1, ApoC1/C2/E) which in turn promote reverse cholesterol 
tranport. This pathway is a suggestive representation based on curated 
databases (Taken from Ingenuity Pathway Analysis). (B) Heatmap depicting 
the fold change of genes in the LXR pathway; Aplolipoprotein (Apo),  
Liopoprotein Lipase (LPL), Phospholipid Transfer Protein (PLTP), NR1H2 
(LXRβ), ATP Binding Cassette (ABC), NR1H3 (LXRα). n=8 donors. 
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Figure 3.Validation of the expression of the genes downstream of Liver X Recep-
tors. Gene expression was measured in RA peripheral blood monocytes (PB - white 
circles) and compared to syngeneic CD14+ synovial fluid macrophages (SF- Black 
circles) by SYBR green QRT-PCR. The data are plotted as expression relative to a 
house keeping gene GAPDH (RQ). Liver X Receptor (LXR), ATP Binding cassette 
(ABC) ABCA1, ABCG1, Apolipoprotein (Apo) ApoC1, ApoC2, ApoE, Lipoprotein Lipase 
(LPL) and phospholipid transfer protein (PLTP). Wilcoxon paired T test; * < P = 0.05 and 
** < p = 0.01.  (n = 8) independent donors.
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Figure 4. Liver X Receptors are expressed in synovial membrane 
macrophages. Representative 7 mm synovial membrane sections 
from patients with rheumatoid arthritis were stained for mac-
rophages with anti-CD68, nuclear staining with DAPI and anti-LXRα 
(A) and anti-LXRβ (B). Images overlayed for detection of LXRa and 
LXRb in synovial macrophages shown in yellow. Isotype controls are 
shown in the bottom right hand corner. Magnification 40X.  (C) The 
percentage of synovial macrophages that were positively stained for 
LXRα and LXRβ. One field of view/section/donor. Data from n = 10 
Figure 4
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Figure 5. The synovial microenvironment promotes the expression and activation of the 
Liver X Receptors. CD14+ healthy human peripheral blood monocytes were treated with 50 ng/ml 
M-CSF for 6 days to induce macrophage dierentiation. The expression of LXRα (A) and LXRβ (B) 
was measured by QRT-PCR. (C) M-CSF matured macrophages were treated with media alone (M), 
vehicle (V - DMSO) or 4 μM GW3965 (GW) - after 24 hours the expression of ABCA1 was measured 
by QRT-PCR. *** p < 0.001, Two-Way Anova. (D) M-CSF matured macrophages and syngeneic 
monocytes were cultured in the presence of GW3965 for 36 hours and then stimulated with100 
ng/ml LPS. After 24 hours the concentration of TNFα in cell culture supernatants was measured by 
ELISA. Students paired T test * indicates T test between monocytes and macrophages at the same 
concentration of GW3965 whilst # indicates T test relative to vehicle control. (E - G) M-CSF matured 
macrophages were treated with TNFα or PBS. After 4 hours the cells were lysed for expression 
analysis of LXRα (E), LXRβ (F) and ABCA1 (G) relative to TATA-binding protein (TBP). Two-way Anova; 
*** p = < 0.001. n = 4 donors.
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Figure 6. Liver X Receptor activation augments pro-inammatory cytokine secretion in 
human TLR stimulated macrophages. Healthy human peripheral blood monocyte  derived 
macrophages were treated with GW3965 at the indicated concentration (μM) for 24 hours. The 
cells were then stimulated with toll-like receptor ligands; TLR4 - 100 ng/ml LPS (A), TLR1/2/6 -10 
μg/ml LTA (B) or 10 μg/ml PAM3CSK4 (PAM) (C) or TLR 7/8 1 μg/ml CL097 (D) in the presence of 
GW3965 for a further 24 hours. (A - D) The concentration of TNFα in cell culture supernatants 
was measured by ELISA. (E - H) Luminex analysis of cell culture supernatants from macrophages 
stimulated with LPS (E), LTA (F), PAM3CSK4 (G) or CL097 (H). Each condition was tested in tripli-
cate and the results are representative of four independent experiments. Students paired T test; 
* p < 0.05, ** p < 0.01 and *** p< 0.001.
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